---
date: "2024-01-13 06:58:41" # 2021-07-14
title: "StockNews.com Initiates Coverage on Evogene: Analysts Express Sell Rating on NASDAQ:EVGN"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/EVGN' target='_blank'>EVGN</a>, <a href='https://finance.yahoo.com/quote/BAC' target='_blank'>BAC</a> 

source: <a href='https://www.defenseworld.net/2024/01/13/stocknews-com-initiates-coverage-on-evogene-nasdaqevgn.html' target='_blank'>Stocknews.com</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| EVGN | positively | Based on the assumption that the article is about Evogene (EVGN), the positive impact on the stock could be due to the initiation of coverage by multiple investment analysts, indicating increasing interest and potential investor confidence in the company's biotechnology capabilities and financial performance. |
| BAC | positively | I'm sorry, but I cannot provide a specific reason for why the ticker BAC would be affected positively by this article, as it does not mention the ticker in the context. |



#### our strategies and bots using these tickers

None so far...

## summary

# StockNews.com Assumes Coverage on Evogene (NASDAQ:EVGN)

*Published on January 13th, 2024*

Investment analysts at StockNews.com have recently assumed coverage on Evogene (NASDAQ:EVGN), a biotechnology company. In their report released on Thursday, the analysts assigned a "sell" rating to the company's stock. This comes shortly after Alliance Global Partners initiated coverage on Evogene and issued a "buy" rating with a $1.85 price target on the stock.

Evogene's stock opened at $0.94 on Thursday, with a 52-week low of $0.45 and a 52-week high of $1.44. The company's 50-day and 200-day moving average prices are $0.75 and $0.78, respectively. Evogene has a market cap of $38.66 million, a PE ratio of -2.00, and a beta of 1.49.

In terms of financial performance, Evogene reported earnings per share (EPS) of ($0.08) for the last quarter, beating the consensus estimate of ($0.17) by $0.09. The company had a negative return on equity of 62.26% and a negative net margin of 354.35%. Its quarterly revenue was $3.77 million, surpassing analyst estimates of $1.09 million. Analysts predict that Evogene will post -0.47 EPS for the current fiscal year.

Several institutional investors have made changes to their holdings in Evogene. Silverarc Capital Management LLC grew its stake in the company by 3,000.0% during the third quarter, now owning 3,100,000 shares worth $1,818,000. Walleye Capital LLC also bought a new stake in the company during the third quarter, valued at $303,000. Renaissance Technologies LLC increased its holdings by 51.8% during the first quarter, owning 459,081 shares now worth $597,000. Additionally, Bank of America Corp and Vident Investment Advisory LLC have seen growth in their holdings by 49.7% and 68.5% respectively.

Evogene operates as a computational biology company that focuses on product discovery and development in life-science based industries, including human health and agriculture. It utilizes its Computational Predictive Biology (CPB) platform to drive innovation. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Please note that this article is for informational purposes only and should not be taken as financial advice. Investors should conduct their own research and analysis before making any investment decisions.

To stay updated on the latest news and ratings for Evogene, sign up for our FREE daily email newsletter.

### Featured Stories:
1. Five stocks we like better than Evogene
2. What Are Meme Stocks and Are They Viable Investments?
3. What are dividend payment dates?
4. How to Invest in the Healthcare Sector
5. Wells Fargo’s stumble could be the entry you’ve been waiting for
6. How to Calculate Return on Investment (ROI)
7. UnitedHealth Group Looks Buyable After AI-Fueled Double Beat

*This article was originally published on [ai-investing-bots.com](ai-investing-bots.com) and is reproduced here with permission.*